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Introduction: 5-oxoproline (pyroglutamic acid), an organic acid intermediate of the gamma-glutamyl cycle, is a rare
cause of high anion gap metabolic acidosis. Acetaminophen and several other drugs have been implicated in the
development of transient 5-oxoprolinemia in adults. We believe that reporting all cases of 5-oxoprolinemia will
contribute to a better understanding of this disease. Here, we report the case of a patient who developed transient
5-oxoprolinemia following therapeutic acetaminophen use.
Case presentation: A 75-year-old Caucasian woman was initially admitted for treatment of an infected hip prosthesis
and subsequently developed transient high anion gap metabolic acidosis. Our patient received 40g of acetaminophen
over a 10-day period. After the more common causes of high anion gap metabolic acidosis were excluded, a urinary
organic acid screen revealed a markedly increased level of 5-oxoproline. The acidosis resolved completely after
discontinuation of the acetaminophen.
Conclusion: 5-oxoproline acidosis is an uncommon cause of high anion gap metabolic acidosis; however, it is likely
that it is under-diagnosed as awareness of the condition remains low and testing can only be performed at specialized
laboratories. The diagnosis should be suspected in cases of anion gap metabolic acidosis, particularly in patients with
recent acetaminophen use in combination with sepsis, malnutrition, liver disease, pregnancy or renal failure. This case
has particular interest in medicine, especially for the specialties of nephrology and orthopedics. We hope that it will
add more information to the literature about this rare condition.
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Transient 5-oxoprolinemia is a rare clinical condition
caused by glutathione deficiency. It usually presents as
severe anion gap metabolic acidosis. The clinical mani-
festations usually reflect the acidosis and include altered
mental state and hyperventilation. Several drugs have
been implicated in the development of this disorder in pa-
tients who are predisposed. The diagnosis can be confirmed
by testing the urine for organic acids. Discontinuation of
the responsible medication leads to complete clinical and
biochemical recovery.Case presentation
A 75-year-old Caucasian woman underwent a dynamic
hip screw operation for treatment of an intertrochanteric
fracture of her left hip. Six weeks later, she experienced a* Correspondence: tarig1982@hotmail.com
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throplasty. She was discharged to a rehabilitation center
but readmitted four weeks later with suspected prosthesis
infection.
Blood tests on admission showed neutrophil leukocytosis
at 18.5×109/L, elevated C-reactive protein at 210mg/L and
bicarbonate of 24 mmol/L. Our patient underwent a hip
revision.
Intra-operative specimens and blood cultures identified
coagulase-negative Staphylococcus aureus that was sensi-
tive to vancomycin. She started vancomycin (1g intraven-
ously twice daily), along with acetaminophen (1g every six
hours) for pain control. Her other blood work, including
liver and kidney function tests, matched her baseline
results, with normal liver function test results and a serum
creatinine of 152μmol/L.
Her past medical history included chronic kidney
disease with a baseline creatinine level between 130 and
150μmol/L, hypertension, non-insulin-dependent diabetestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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obstructive pulmonary disease, and folate deficiency. Her
prescription medications included aspirin 75mg, bisopro-
lol 10mg, atorvastatin 10mg, furosemide 40mg twice daily,
gliclazide modified release 90mg, pantoprazole 40mg, folic
acid 5mg, combivent nebulizer, and OxyNorm® (oxy-
codone) 10mg as needed.
On day 10 of admission, our patient’s condition deterio-
rated and she became drowsy, confused and disorientated,
and was hyperventilating. A physical examination revealed a
Glasgow Coma Scale score of 12. Her vital signs were as
follows: temperature, 36.2°C; blood pressure, 145/66mmHg;
pulse, 80 beats per minute; respiratory rate, 24 breaths per
minute; and oxygen saturation (SaO2), 99% on room air.
Our patient moved all of her extremities spontaneously.
The rest of her physical examination was unremarkable.
An electrocardiogram showed sinus rhythm of 90 beats
per minute. A chest X-ray revealed mild cardiomegaly with
no signs of infection or congestion. Repeat blood tests
showed the following: sodium, 142mmol/L; potassium,
3.5mmol/L; chloride, 118mmol/L; CO2, 5mmol/L; urea,
8mmol/L; and creatinine, 150μmol/L. Liver function find-
ings were unremarkable except for hypoalbuminemia at
17g/L. Full blood count findings showed hemoglobin of
10g/dL, neutrophil leukocytosis at 16.5×109/L and platelets
of 485×109/L. Arterial blood gas showed metabolic acidosis
with respiratory compensation (pH, 7.18; partial pressure of
carbon dioxide, 1.7kPa; partial pressure of oxygen, 16.7kPa;
bicarbonate, 8.3mmol/L; base excess, −22.7mmol/L; SaO2,
98.6% in room air). The corrected anion gap for
hypoalbuminemia was 25mmol/L. The following causes of
high anion gap metabolic acidosis (HAGMA) were exclu-
ded: lactic acid 0.7mmol/L, blood ketones <0.2mmol/L,
salicylate <0.4mmol/L.
It was felt that her unchanged creatinine of 150μmol/L
was insufficient to explain the marked deterioration in her
acid–base status. A urine analysis and serum toxicology
screen were unremarkable, including her serum acetaFigure 1 Gamma-glutamyl cycle. This figure shows the various compounminophen level. The osmolar gap was mildly elevated at 21
mOsm/kg. Because her serum toxicology screen was nega-
tive, our patient’s urine was sent for organic acid detection
by gas chromatography–mass spectrometry, which demon-
strated a markedly increased excretion of 5-oxoproline at
the peak of her acidosis, 10 days into her admission.
The acute management (based on the differential diag-
nosis and our patient’s condition) included commence-
ment on bicarbonate (8.4% infusion of which she received
a total of 600 milliequivalents over 48 hours), supportive
intravenous fluids, and discontinuation of acetaminophen.
Over the following two days, her acidosis resolved with
an overall improvement in her clinical condition. Repeat
arterial blood gas showed the following: pH, 7.40; partial
pressure of carbon dioxide, 3.8 kPa; partial pressure of oxy-
gen, 12.7kPa; and bicarbonate, 20mmol/L. The acidosis
correction persisted on subsequent testing over the
remainder of her admission, indicating that the causative
agent (acetaminophen) had been removed. The diagnosis
of 5-oxoprolinemia was confirmed on receipt of organic
acid test results two weeks later.
Discussion
Elevated levels of plasma lactate, ketones and uremia are
common causes of HAGMA. A less frequent cause is the
temporary accumulation of the organic acid 5-oxoproline
[1,2]. 5-oxoproline is primarily metabolized to glutamate
by the enzyme 5-oxoprolinase and is eliminated by the
renal system.
5-oxoprolinemia is classically caused by lack of gluta-
thione [3]. 5-oxoproline is an intermediate in the
gamma-glutamyl pathway, which is the metabolic cycle
responsible for generating glutathione and membrane
transport of amino acids into the cytosol [4]. In this
pathway, normal glutathione stores are required for feed-
back suppression of the enzyme gamma-glutamylcysteine
synthetase, which controls the activity of the cycle (see
Figure 1).ds, enzymes and coenzymes that are required to form glutathione.
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glutathione synthetase leads to accumulation of gamma-
glutamylcysteine and its conversion to 5-oxoproline
through an alternative pathway.
There is some polymorphism for the glutathione
synthetase enzyme, so some cases of HAGMA with 5-
oxoprolinemia occur later in life under particular metabolic
stress, suggesting a previously unrecognized genetic defect
[5]. Aside from the polymorphism, there also exists
acquired glutathione synthetase deficiency because the
enzyme may not perform equally well across the person’s
life span.
Hereditary 5-oxoprolinemia is a result of autosomal
recessive deficiencies caused by hereditary error in one
of the enzymes involved in the gamma-glutamyl cycle,
but these rare cases usually present in childhood with
hemolytic anemia and neurological defects.
In the adult population, a clinically significant acquired
transient form of 5-oxoprolinemia may occur, with
resultant accumulation of 5-oxoproline and subsequent
development of anion gap acidosis. This temporary form
of 5-oxoprolinemia may be encountered at any age, and
is believed to result from disturbance of the gamma-
glutamyl cycle. Risk factors that predispose to glutathione
depletion include malnutrition, diabetes, pregnancy and
liver disease. Renal impairment also causes reduced urin-
ary excretion of 5-oxoproline. We need to emphasize that
our patient demonstrated a number of these risk factors:
she was elderly and malnourished, and had diabetes and
chronic kidney disease as well as sepsis, and had been
unwell for three months.
Several drugs have been implicated in temporary
5-oxoprolinemia. The antibiotics flucloxacillin and netil-
micin are thought to inhibit the enzyme 5-oxoprolinase
and hence lead to accumulation of 5-oxoproline. Acet-
aminophen and vigabatrin deplete glutathione stores leading
to loss of feedback inhibition and increased production of
5-oxoproline from its precursor gamma glutamylcysteine.
Most of the described cases of transient 5-oxoprolinemia
are caused by repeated therapeutic acetaminophen ingestion,
usually arising on the background of the aforementioned risk
factors [6-8]. The cases of HAGMA with 5-oxoprolinemia
after acetaminophen use generally do not have other indica-
tors of acetaminophen toxicity, such as elevated hepatic
transaminases or abnormal prothrombin time.
A diagnosis of 5-oxoprolinemia should be considered in
any patient with unexplained metabolic acidosis and a
history of therapeutic acetaminophen dosing, particularly
those patients with coexisting conditions that may decrease
the glutathione stores. Patient management should com-
prise prompt discontinuation of medications that are linked
to the development of the condition along with supportive
care. Any underlying infection or medical condition must
be identified and treated appropriately.There is no evidence to support that N-acetylcysteine
treats or corrects 5-oxoprolinemia. Some studies recom-
mend N-acetylcysteine supplementation to provide the
cysteine necessary for glutathione synthesis [9,10]. How-
ever, these studies do not prove that N-acetylcysteine
changes the metabolic fate of gamma glutamylcysteine
(which already contains cysteine). In patients who are
accumulating gamma glutamylcysteine because they lack
the last building block for glutathione, despite normal
glutathione synthetase activity, glycine may be needed
(see Figure 1).
Conclusion
A diagnosis of 5-oxoprolinemia should be considered in
patients with unexplained HAGMA, particularly patients
with recent acetaminophen use in combination with sep-
sis, malnutrition, liver disease, pregnancy or renal failure.
Simple urinary tests for organic acids can support the
diagnosis of 5-oxoprolinemia. Patient management should
include discontinuation of the offending medications,
supportive management, and aggressive treatment of the
associated risk factors, for example, sepsis. The role of
N-acetylcysteine in the management of 5-oxoprolinemia
without acetaminophen-induced hepatic injury is unclear.
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